

33. Filipe Oto Cunha de Moraes, Guilherme Tetsuo Yokoyama, Larissa Tami Hokama FGS. Effects of IL-7 on sepsis: a systematic review. *Rev Med (São Paulo)*. 2021.
34. Lešník PL, Janc J, Mierzchala-Pasierb M, Tański WT, Wierciński JW, Łysenko L. Interleukin-7 and interleukin-15 as prognostic biomarkers in sepsis and septic shock: Correlation with inflammatory markers and mortality. 2023;169
35. Daix T, Mathonnet A, Brakenridge S, Dequin PF, Mira JP, Berbille F, et al. Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. *Ann Intensive Care*. 2023;13.
36. Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. *JCI Insight*. 2018. <https://doi.org/10.1172/jci.insight.98960>.
37. Laterre PF, François B, Collienne C, Hantson P, Jeannet R, Remy KE, et al. Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19). *JAMA Netw Open*. 2020;3:2016485-2016485.
38. Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. *Nat Immunol*. 2019;20:1584-93.
39. Hotchkiss RS, Opal S. Immunotherapy for Sepsis – A New Approach against an Ancient Foe. *New England Journal of Medicine*. 2010;363:87-9.
40. Shankar-Hari M, Francois B, Remy KE, Gutierrez C, Pastores S, Daix T, et al. A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19. *JCI Insight*. 2025;10.
41. Hutchins NA, Unsinger J, Hotchkiss RS, Ayala A. The new normal: Immunomodulatory agents against sepsis immune suppression. *Trends in Molecular Medicine*. 2014;20:224-33.
42. Inoue S, Unsinger J, Davis CG, Muenzer JT, Ferguson TA, Chang K, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. *J Immunol*. 2010;184:1401-9.
43. Zhao X, Qi H, Zhou J, Xu S, Gao Y. Treatment with Recombinant Interleukin-15 (IL-15) Increases the Number of T Cells and Natural Killer (NK) Cells and Levels of Interferon-γ (IFN-γ) in a Rat Model of Sepsis. *Med Sci Monit*. 2019;25:4450-6.
44. Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. *Blood*. 2018;131:2515-27.
45. Patil NK, Bohannon JK, Luan L, Guo Y, Fensterheim B, Hernandez A, et al. Flt3 Ligand Treatment Attenuates T Cell Dysfunction and Improves Survival in a Murine Model of Burn Wound Sepsis. *Shock*. 2017;47:40-51.
46. Hundeshagen G, Cui W, Musgrove L, Cherry A, Lee S-J, Cox RA, et al. Fms-Like Tyrosine Kinase-3 Ligand Attenuates Local and Systemic Infection in a Model of Post-Burn Pneumonia. *Shock*. 2018;49:721-7.
47. Patil NK, Bohannon JK, Luan L, Guo Y, Sherwood ER. Preclinical Evaluation of Flt3 Ligand to Improve T Cell Adaptive Immune Response During Sepsis. *The FASEB Journal*. 2016;30:1202.3-1202.3.
48. Joshi I, Carney WP, Rock EP. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis. *Front Immunol*. 2023;14:1-15.
49. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. *Am J Respir Crit Care Med*. 2009;180:640-8.
50. Bhattacharya P, Budnick I, Singh M, Thirupathi M, Alharshawy K, Elshabrawy H, et al. Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. *Journal of Interferon and Cytokine Research*. 2015;35:585-99.
51. Mu X, Liu K, Li H, Wang FS, Xu R. Granulocyte-macrophage colony-stimulating factor: an immunotarget for sepsis and COVID-19. *Cellular & Molecular Immunology*. 2021;18:2057-8.
52. Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. *Intensive Care Med*. 2011;37:525.
53. Vacheron CH, Lepape A, Venet F, Monneret G, Gueyffier F, Boutitie F, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: The GRID randomized controlled trial. *J Crit Care*. 2023;78:154330.
54. Souza-Fonseca-Guimaraes F, Parlato M, Philippart F, Misset B, Cavaillon JM, Adib-Conquy M, et al. Toll-like receptors expression and interferon-γ production by NK cells in human sepsis. *Crit Care*. 2012;16:R206.
55. Payen D, Faivre V, Miatello J, Leentjens J, Brumpt C, Tissières P, et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. *BMC Infect Dis*. 2019;19:10.
56. Roquilly A, Francois B, Huet O, Launey Y, Lasocki S, Weiss E, et al. Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial. *Intensive Care Med*. 2023;49:530-44.
57. Kotsaki A, Pickkers P, Bauer M, Calandra T, Lupse M, Wiersinga WJ, et al. ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol. *BMJ Open*. 2022;12:e067251.
58. Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. *Crit Care*. 2013;17.
59. Wu J, Pei F, Zhou L, Li W, Sun R, Li Y, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. 2017;13
60. Jarczok D, Kluge S, Nierhaus A. Use of intravenous immunoglobulins in sepsis therapy—a clinical view. *Int J Mol Sci*. 2020;21:1-17.
61. Werdan K, Pilz G, Bujdosó O, Fraunberger P, Neeser G, Schmieder RE, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. *Crit Care Med*. 2007;35:2693-701.
62. Brocklehurst P, Farrell B, King A, Juszczak E, Darlow B, Haque K, et al. Treatment of neonatal sepsis with intravenous immune globulin. *N Engl J Med*. 2011;365:1201-11.
63. Průcha M, Zazula R, Sedláčková L. Aktuální postavení a používání intravenózních imunoglobulinů nejen v intenzivní medicíně. *Anest. Intenziv. Med*. 2012;23:300-6.
64. Pan B, Sun P, Pei R, Lin F, Cao H. Efficacy of IVIG therapy for patients with sepsis: a systematic review and meta-analysis. *J Transl Med*. 2023;21:1-13.
65. Cui J, Wei X, Lv H, Li Y, Li P, Chen Z, et al. The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis. *Ann Intensive Care*. 2019;9:27.
66. Shankar-Hari M, Culshaw N, Post B, Tamayo E, Andaluz-Ojeda D, Bermejo-Martin JF, et al. Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis. *Intensive Care Med*. 2015;41:1393-401.
67. Nierhaus A, Berlot G, Kindgen-Milles D, Müller E, Girardis M. Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis. *Ann Intensive Care*. 2020;10:1-19.
68. Vladimirova IL, Sosunova E, Nikolaev A, Nenashva T. Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation. *J Immunol*. 2016;171:1580.
69. Khosrojerdi A, Soudi S, Hosseini AZ, Eshghi F, Shafiee A, Hashemi SM. Immunomodulatory and Therapeutic Effects of Mesenchymal Stem Cells on Organ Dysfunction in Sepsis. *Shock*. 2021;55:423-40.
70. Sun J, Ding X, Sun T. Mesenchymal Stem Cells in Sepsis: From Basic Research to Clinical Application. *Intensive Care Research*. 2021;1:2.
71. McIntyre LA, Stewart DJ, Mei SHJ, Courtman D, Watpool I, Granton J, et al. Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. *Am J Respir Crit Care Med*. 2018;197:337-47.
72. De Zuani M, Hortová-Kohoutková M, Andrejčinová I, Tomášková V, Šrámek V, Helán M, et al. Human myeloid-derived suppressor cell expansion during sepsis is revealed by unperturbed clustering of flow cytometric data. *Eur J Immunol*. 2021;51:1785-91.
73. Schrijver IT, Théroude C, Roger T. Myeloid derived suppressor cells in sepsis. *Frontiers in Immunology*. 2019;10.
74. Pfortmueller CA, Meisel C, Fux M, Schefold JC. Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers. *Intensive Care Medicine Experimental*. 2017;5.
75. Liu D, Huang SY, Sun JH, Zhang HC, Cai QL, Gao C, et al. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. *Mil Med Res*. 2022;9.
76. Ono S, Tsujimoto H, Hiraki S, Aosasa S. Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis. *Ann Gastroenterol Surg*. 2018;2:351-8.
77. Kyriazopoulou E, Giamarellos-Bourboulis EJ. Monitoring immunomodulation in patients with sepsis. *Expert Rev Mol Diagn*. 2021;21:17-29.
78. Gao X, Cai S, Li X, Wu G. Sepsis-induced immunosuppression: mechanisms, biomarkers and immunotherapy. *Front Immunol*. 2025;16:1577105.
79. He L, Guo C, Su Y, Ding N. The relationship between serum ferritin level and clinical outcomes in sepsis based on a large public database. *Sci Rep*. 2023;13:1-12.
80. Fischer J, Hortová Kohoutková M, Frič J, Šrámek V, Helán M. Postsepsis syndrom. *Anest. intenziv. Med*. 2025;36(1):15-21. doi: 10.36290/aim.2024.064.
81. van den Haak DAC, Otten LS, Koenen HJPM, Smeets RL, Piet B, Pickkers P, et al. Evidence-based rationale for low dose nivolumab in critically ill patients with sepsis-induced immunosuppression. *Clin Transl Sci*. 2023;16:978-86.
82. Kasi AFUD, Nagi MI, Kasi BA. Nivolumab-Induced Pneumonitis in a Patient With Urothelial Cancer. *Cureus*. 2023;15:e39511.
83. Mathias B, Szpila BE, Moore FA, Efron PA, Moldawer LL. A review of GM-CSF therapy in sepsis. *Medicine (United States)*. 2015;94:1-10.
84. Riddell LA, Pinching AJ, Hill S, Ng TT, Arbe E, Lapham GP, et al. A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. *AIDS Res Hum Retroviruses*. 2001;17:789-97.
85. Delsing CE, Gresnigt MS, Leentjens J, Preijers F, Frager FA, Kox M, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. *BMC Infect Dis*. 2014;14:166.
86. Keegan A, Ricciuti B, Garden P, Cohen L, Nishihara R, Adeni A, et al. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. *J Immunother Cancer*. 2020;8.
87. Venet F, Foray A-P, Villars-Méchin A, Malcus C, Poitevin-Later F, Lepape A, et al. IL-7 restores lymphocyte functions in septic patients. *J Immunol*. 2012;189:5073-81.